Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial by Grogono, Joanna C. et al.
RESEARCH Open Access
Inhaled furosemide for relief of air hunger
versus sense of breathing effort: a
randomized controlled trial
Joanna C. Grogono1* , Clare Butler2, Hooshang Izadi3 and Shakeeb H. Moosavi1
Abstract
Background: Inhaled furosemide offers a potentially novel treatment for dyspnoea, which may reflect modulation
of pulmonary stretch receptor feedback to the brain. Specificity of relief is unclear because different neural
pathways may account for different components of clinical dyspnoea. Our objective was to evaluate if inhaled
furosemide relieves the air hunger component (uncomfortable urge to breathe) but not the sense of breathing
work/effort of dyspnoea.
Methods: A randomised, double blind, placebo-controlled crossover trial in 16 healthy volunteers studied in a
university research laboratory. Each participant received 3 mist inhalations (either 40 mg furosemide or 4 ml
saline) separated by 30–60 min on 2 test days. Each participant was randomised to mist order ‘furosemide-
saline-furosemide’ (n- = 8) or ‘saline-furosemide-saline’ (n = 8) on both days. One day involved hypercapnic air
hunger tests (mean ± SD PCO2 = 50 ± 3.7 mmHg; constrained ventilation = 9 ± 1.5 L/min), the other involved
work/effort tests with targeted ventilation (17 ± 3.1 L/min) and external resistive load (20cmH2O/L/s). Primary
outcome was ratings of air hunger or work/effort every 15 s on a visual analogue scale. During saline
inhalations, 1.5 mg furosemide was infused intravenously to match the expected systemic absorption from
the lungs when furosemide is inhaled. Corresponding infusions of saline during furosemide inhalations
maintained procedural blinding. Average visual analogue scale ratings (%full scale) during the last minute of
air hunger or work/effort stimuli were analysed using Linear Mixed Methods.
Results: Data from all 16 participants were analysed. Inhaled furosemide relative to inhaled saline significantly
improved visual analogues scale ratings of air hunger (Least Squares Mean ± SE − 9.7 ± 2%; p = 0.0015) but not
work/effort (+ 1.6 ± 2%; p = 0.903). There were no significant adverse events.
Conclusions: Inhaled furosemide was effective at relieving laboratory induced air hunger but not work/effort in
healthy adults; this is consistent with the notion that modulation of pulmonary stretch receptor feedback by inhaled
furosemide leads to dyspnoea relief that is specific to air hunger, the most unpleasant quality of dyspnoea.
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Background
Dyspnoea accounts for over 15% of symptom burden
among hospitalized patients and contributes to poor qual-
ity of life by limiting activity, increasing anxiety levels and
undermining the will to live [1, 2]. It is present in a wide
range of conditions such as chronic obstructive pulmon-
ary disease (COPD), chronic heart failure, advanced can-
cer and neuromuscular disease [3]. Given its prevalence
and impact, there is an urgent clinical need for more ef-
fective treatments. Inhaled furosemide offers a potential
complementary treatment for dyspnoea relief [4].
Furosemide is a loop diuretic. It is usually taken orally
or intravenously and acts through inhibition of the
sodium-potassium-chloride co-transporter in the thick as-
cending limb of the loop of Henle in the kidneys [5]. In
rats, inhaled furosemide has been shown to sensitize
slowly adapting pulmonary stretch receptors (saPSR) in
the lung parenchyma [6]. Stimulation of these receptors
has been shown to relieve air hunger (AH; an uncomfort-
able urge to breathe) in high level quadriplegic humans in
whom afferent information from the chest wall is blocked
but vagal afferents from lungs remain intact [7]. Along
with AH, clinical dyspnoea is comprised of other distin-
guishable components including the sense of breathing
work/effort (WE) and chest ‘tightness’ [8]. These compo-
nents can vary based on interactions between physio-
logical, psychological, social and environmental factors
[9]. The mechanisms underlying dyspnoea are complex
with multiple voluntary and involuntary triggers as well as
feed-forward and feed-back mechanisms [9]. Measuring
breathlessness is difficult as the sensation of breathless-
ness is subjective and does not correlate well with object-
ive measures of lung or heart function [10, 11]. The
distinct components of clinical dyspnoea are thought to
arise from separate neural pathways [8]. This theory
comes from studies showing that despite complete paraly-
sis of the respiratory muscles, subjects show the same AH
stimulus-response to CO2 and that increasing the tidal
volume using a ventilator can relieve AH in C1-C2 quadri-
plegics, suggesting a vagal pathway rather than feedback
from chest wall afferents [7, 12, 13]. For AH a collorary
discharge of the drive to breathe from the brain stem has
been proposed [14] whereas for WE a corollary discharge
from the motor cortex driving voluntary breathing has
been proposed as the source of the sensation [12].
The optimal solution for relief of dyspnoea is to treat
the underlying pathology but this is not always possible
and does not always lead to symptom relief. In chronic
conditions, such as heart failure or COPD, symptom con-
trol becomes a priority in order to improve quality of life.
A newer focus is to alter the perception of dyspnoea via al-
tering the activity of neural signals sent to the brain
reporting the prevailing level of breathing. The mechan-
ism of action of inhaled furosemide has not been fully
elucidated but current theory suggests that it acts by
modulating pulmonary stretch receptor activity. There is
evidence to support this theory, both in animal and hu-
man studies [6, 15].
The current study hypothesized that inhaled furosem-
ide would relieve AH but not the sense of breathing ef-
fort. The result of this study has been previously
reported in the form of an abstract [16].
Methods
Sixteen healthy volunteers (9 male) attended the Oxford
Brookes Cardiorespiratory Research Laboratory on 4 occa-
sions. Eligibility criteria included; age above 18 years, no
regular prescription medication in the previous 2 weeks
and if female, not pregnant or planning pregnancy. Oxford
Brookes University Research Ethics committee approved
the protocol and all participants provided written in-
formed consent.
All participants and all healthcare professionals apart
from those who administered the interventions were
blinded to the medications. Each participant visited the
laboratory on 4 occasions; two practice sessions to famil-
iarise themselves with the equipment and to become ac-
customed to rating the sensation of dyspnoea and; two
‘test’ sessions where participants inhaled the mists, with
different dyspnoea stimuli (AH or WE) on different days
in random order. On these days the participants were
randomised to either inhale aerosolized mist (nebuliser)
in the order of furosemide (40 mg, 10 mg/ml; hameln
pharmaceuticals gmbh, Langes Feld, Hameln, Germany),
saline (4 ml; B.Braun, Melsungen, Germany), furosemide
(FSF) or saline, furosemide, saline (SFS) for both study
days. Prior to each mist inhalation they gargled with a
menthol mouthwash. The nebulisation duration of the
furosemide mist was approximately 10-15 min and the
saline mist 5-10 min. Each mist inhalation started after
6–11 min of the steady state test level of each pre-mist
AH or WE test. The post mist steady state test level was
between 9 and 14 min after the end of the mist inhala-
tions. Each AH or WE test lasted 10 min, with a total
visit duration of around 3 h (7 AH or WE tests, and 3
mist inhalations.)
Dyspnoea stimuli
Two different dyspnoea stimuli were tested in each vol-
unteer on different days.
1) Air Hunger (AH).
Participants were semi-reclined in a padded chair,
whilst wearing a nose clip, and breathing via a mouth-
piece. Humidified warmed gas was delivered into a 3 l
anaesthetic bag supplying the inspiratory gas via a
one-way valve. Expired gas was expelled via a second
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one-way valve (Fig. 1). Minute ventilation was therefore
constrained as it could not exceed the flow into the bag.
The participant’s respiratory rate was fixed by breathing
in time with a metronome. The frequency and tidal vol-
ume were therefore fixed. Participants were informed
that the amount of air at times would be limited and
were coached not to pull excessive pressure with inef-
fective efforts against the collapsed bag. During the
study carbon dioxide was added to the inspired air. Ini-
tially a gradual increase in inspired CO2 was performed
until the maximal tolerated level of dyspnoea and then
two 5 min steady state levels of end tidal CO2 (ETCO2)
were chosen to target a level of 50% (‘test’ level) and
25% (‘masking’ level) of the visual analogue scale (VAS)
for AH. The ‘masking’ level served to prevent the partic-
ipants from expecting a certain result. The order of the
5 min test and masking steps were altered between runs.
This method has been shown to produce strong AH
stimulation without significant WE sensation [17]. Brief
periods of unrestrained breathing separated the two
levels of hypercapnia during which participants per-
formed an inspiratory capacity manoeuvre in order to fa-
cilitate rapid change in inspired CO2 level and to reduce
the chance of atelectasis (Fig. 2).
2) Work Effort (WE)
Participants were semi-reclined in a padded chair,
whilst wearing a nose clip, and breathing via a mouth-
piece. Humidified warmed gas was delivered into a 3 l
anaesthetic bag supplying the inspiratory gas via a
one-way valve. Two resistors (12cmH2O and 8cmH2O at
1 L/s in series) were added to the inspiratory side of the
circuit, giving an estimated total resistance of 20cmH2O
as it has been shown that resistances of series combin-
ation are approximately equivalent to the algebraic sum
of the individual resistors [18]. Expired gas was expelled
via a second one-way valve. The participant was
instructed to just empty the anaesthetic bag with each
breath and a metronome fixed the frequency of each
breath. Therefore, the amount of gas flowing into the
bag determined the targeted minute ventilation. This
target flow began at a level that matched the individual’s
baseline alveolar ventilation and then was gradually in-
creased until the participant could no longer empty the
bag (or a maximum of 20 l/min –the limit of the flow-
meter device). This was followed by two 5-min steady
state levels of targeted ventilation, a ‘test’ level that gen-
erated 50% WE on the visual analogue scale and a
‘masking’ level generating 25%. These two steady state
levels were imposed in random order to prevent the par-
ticipants from expecting a certain result. This stimulus
was always limited by participants failing to meet a
Fig. 1 Breathing circuit. The Breathing Circuit was identical for air hunger (AH) test and work/effort (WE) test, except that the external resistance
was removed in the AH test. To elicit AH, CO2 was added to the flow of fresh gas into the bag and this flow was fixed at baseline alveolar
ventilation. To elicit WE, individuals were instructed to empty the bag with each breath while the flow of fresh bag into the bag was increased
and CO2 was added to maintain normocapnia. PETCO2 = end tidal PCO2
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higher ventilation target and not because they reached
the top of the VAS for WE. Normocapnia (mean ± SD:
41.9 ± 1.2 mmHg) was maintained throughout. Brief pe-
riods of unrestrained breathing separated the two levels
of ventilation during which participants performed an
inspiratory capacity manoeuvre in order to match the
design of the AH test (Fig. 2).
Intravenous infusions
During each inhalation period, participants also received a
15-min (1 ml/min) intravenous infusion of 0.1 mg/ml so-
lution furosemide if inhaled substance was 0.9% sodium
chloride, or 0.9% sodium chloride if inhaled substance was
furosemide (i.e. SFS infusions for FSF inhalations versus
FSF infusions for SFS inhalations.) Infusions were admin-
istered via a catheter inserted in the antecubital vein using
a syringe driver (Graseby In-line Pressure Syringe Pump
3200, Graseby Medical Ltd., Ashford, UK). 1.5 mg fur-
osemide was infused over a period of time set to match
the duration of inhalation. This dose was chosen as this
was the amount expected to be systemically absorbed
from a 40 mg nebuliser dose [19]. This ensured that both
participants and the researchers did not know which mist
was furosemide or 0.9% sodium chloride since the sys-
temic effects (diuresis) were similar in each case. It also
allowed an assessment of the systemic effect on furosem-
ide on dyspnoea relief.
Measurements
A 100 mm electronic VAS was used to obtain subjective
ratings of both AH (during AH tests) and WE (during
WE tests). Ratings were cued by a ‘rate now’ light every
15 s, which instructed participants to rate how much
AH or WE they were feeling at that point in time,
throughout the 10 mins of each AH and WE test. In the
practice sessions, participants were immediately asked to
select descriptors from a set list for any of the sensations
they felt during that test. In future test sessions they
were asked to focus on those descriptors that matched
the AH sensation for the AH test and WE sensation for
the WE test. The range covered 0 mm (no breathless-
ness) to 100 mm (tolerable limit) as previously described
[17, 20, 21]. Additional word anchors (‘slight’, ‘moderate’
and ‘severe’) were placed at equal separation alongside
the scale, which enabled participants to remember how
much of the scale represented how much sensation from
one occasion to the next. The order of test sessions (AH
or WE) were randomly allocated and counterbalanced.
Airflow was measured via a pneumotachometer (Re-
spiratory Flow Head MLT300L, ADinstruments, Ox-
ford, UK) and integrated (FV156 respiratory flow
integrator, Validyne Engineering, CA, USA) to provide
tidal volume (VT). Breathing pattern was recorded by
DC-coupled respiratory inductance plethysmography
((RespiTrace R250, Studley Data Systems, Oxford,
Fig. 2 Standard tests of air hunger and work/effort. Left: Typical raw data set for the air hunger (AH) test during which two levels of end-tidal
PCO2 were imposed and ventilation was constrained. The vertical dashed lines indicate the steady state level of AH associated with the test level
of CO2 chosen to elicit 50%VAS ratings in pre-mist trials. Right: Typical raw data set for the work effort (WE) test in which two levels of targeted
VT were imposed and normocapnia was maintained. The vertical dashed lines indicate the steady state level of WE associated with the test level
of VT chosen to elicit 50% VAS ratings in pre-mist trials. During both tests ventilatory constraint or targeting was suspended briefly and
participants were instructed to take a sigh. VAS ratings were provided every 15 s in response to a LED cue. VT Tidal volume, PAW continuous
airway pressure measured at the mouth
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UK). Mouthpiece pressure was measured via a
fine-bore (1.5 mm) sampling tube inserted into the
mouthpiece connected to a pressure transducer (Dif-
ferential pressure transducer, ±50 cmH20, Validyne
Engineering, CA, USA), Tidal PCO2 and PO2 were
measured with a calibrated, fast-responding, respira-
tory gas analyser (ML206, ADinstruments, Oxford,
UK). Blood pressure, oxygen saturations (SaO2) and
electrocardiogram were also monitored (DatexOh-
meda Cardiocap 5, Madison USA). Signals were digi-
talised and recorded for offline analysis (Micro1401
with Spike 2 software, Cambridge Electronic Design,
Cambridge, UK.)
Participants voided prior to the start of each test
session and the output was measured at approxi-
mately 25 min after each mist inhalation by urinating
into a measuring flask.
Data analysis
The VAS in the last minute of each test step for the two
furosemide mists presented for half the participants were
averaged (those in the FSF group) and for the 2 saline
mists presented for the other half (for those in the SFS
group). The Linear Mixed Model “mixed” procedure of
SAS 9.4 was used to analyse the data. Initially a full
mean model with three factors; two levels of ‘condition’
(AH or WE), two levels of ‘mist’ (Furosemide or Saline),
and 7 levels of ‘time’ (tests A-G; Fig. 3). All the 2-way
and 3-way interactions were examined. Reducing the
mean model by removing non-significant terms indi-
vidually, resulted in the final model with 3 main effects
and one interaction between condition-mist.
Sample size
In a preliminary study 10 healthy volunteers rated 13%
lower AH on VAS with inhaled furosemide relative to
inhaled saline [21], with a standard deviation of 16%
resulting in an effect size of 0.81. Based on this observa-
tion, it was determined that 16 participants were re-
quired to detect an effect size of 0.81 using matched
pairs t-test at 5% significance level and 86% power.
Fig. 3 Effect of mist inhalations on steady state air hunger (AH) and work/effort (WE). This dataset is from an individual who received the mists in
the order of furosemide-saline-furosemide (FSF) with the corresponding saline-furosemide-saline (SFS) intravenous infusions on both days. Panels
a to f show the last minute of each test level of end-tidal CO2 (for AH) or of VT (for WE) –these regions of interest are shown by the vertical
dashed lines in Fig. 2. AH test day: Air hunger ratings were reduced after furosemide inhalation (a to b and e to f) but not after saline inhalation
(c to d). WE test day: No obvious differences in ratings were evident before and after any mist inhalations
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Randomisation
Participants were randomised to mist allocations after
completing the two practice sessions. One of 17 re-
cruited participants did not progress to randomisation
(Fig. 4); this was because despite increasing levels of
hypercapnia (up to PETCO2 of 54 mmHg), they rated
near zero dyspnoea and self-terminated the test due
to light-headedness during practice sessions. When
questioned they denied any experience of dyspnoea
during the test.
The mist order allocation (FSF or SFS) was randomly
assigned by the unblinded researcher to 16 sequential
numbers, ensuring that 8 participants were allocated to
the SFS group and 8 to the FSF group. A blinded re-
searcher assigned each consecutive participant to the
next available allocation number. Apart from the un-
blinded researcher, all other investigators and partici-
pants did not know whether the allocated number
corresponded to FSF or SFS group. Once full analysis
had been completed the principal investigator was pro-
vided with the allocation code.
Participants were provided with detailed written in-
formation about the interventions and protocol. They
were aware they were going to receive furosemide or
a placebo (control substance, saline) to inhale as a
mist and to have as a solution via a vein in the arm
(that was not the same as the mist) 3 times per visit.
The diagram in the patient information leaflet showed
the mist order as A, B, A.
Results
Participants were recruited between 1st October 2015,
and the first participant enrolled on 6th October
2015 and the last participant was enrolled on 26nd
February 2016. The last visit for the last participant
was on 11th March 2016. The median duration for
all visits was 19 days.
The baseline characteristics of the participants who
completed the study are shown in Table 1. The FSF
mist order group and the SFS mist order group were
well matched apart from by chance a higher propor-
tion of participants who were Caucasian in the FSF
compared to the SFS groups (p = 0.031). It is notable
that 2 of the 3 (S9, S12) individuals who had an in-
crease in AH (rather than a relief ) following inhaled
furosemide had a history of asthma. These two and
S15 who also had a history of asthma were in the
SFS group. No other notable differences were ob-
served for individuals with a history of asthma.
Fig. 4 Patient Flow Diagram
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Effect of mist inhalations on AH and WE
A treatment effect (relief with inhaled furosemide rela-
tive to relief by inhaled saline control) was seen with fur-
osemide for the AH test (Fig. 5). Mean VAS for
dyspnoea was significantly lowered by furosemide rela-
tive to saline inhalation (Difference of Least Squares
Mean ± SE of − 9.7 ± 2.1%VAS) for the AH test (p =
0.0015, Tukey-Kramer adjusted), but was not signifi-
cantly changed by furosemide relative to saline inhal-
ation (+ 1.6%VAS ± 2.4SE) for the WE test (p = 0.903,
Tukey-Kramer adjusted). Four of the 16 participants
showed a relief of over 20%VAS with inhaled furosemide
for AH but no relief of this magnitude was seen in any
participants for WE (Fig. 6).
Single versus two doses of furosemide
The average relief of AH from furosemide inhalations
(averaged response for mists 1 and 3; 2x40mg) in the
FSF group was greater than the relief seen with the
single furosemide inhalation (mist 2; 1x40mg) in the
SFS group; this group-wise comparison did not
achieve statistical significance (mean ± SD − 15.5 ± 12
versus − 6.6 ± 27%VAS, unpaired t-test with unequal
variance; p = 0.42). However, within the FSF group, 7
of the 8 participants had substantially greater relief of
AH after the second inhalation (mist 3) of furosemide
compared to the first (mist 1) - a doubling of relief
(mean ± SD − 10 ± 12 versus − 21 ± 13%VAS) which
was highly significant (paired t-test, p = 0.002; Fig. 7).
In contrast, comparing the mean change for WE be-
tween the first and second doses of furosemide in the
FSF group revealed no significant difference (paired
t-test, p = 0.41). There were no significant differences
between the first and second dose of saline within
the SFS group for either AH or WE tests (paired
t-test p = 0.6 and 0.3 respectively).
Distinguishability of stimuli and blinding of participants
AH and WE stimuli were clearly distinguishable; sub-
jective selection of descriptive phrases from a set list im-
mediately following breathing tests verified that the AH
test predominantly elicited phrases consistent with ‘air
hunger’ whereas the WE test predominantly elicited
phrases consistent with ‘work/effort’ (Fig. 8). Choice of
descriptors following AH and WE test showed a low
level of conflation in sensation ratings, with 6% choosing
WE descriptors for the AH test and 10% choosing AH
descriptors for the WE test.
Cumulative urine output was matched for FSF and
SFS groups. There was no significant difference in the
cumulative urine volume between participants in the
FSF versus the SFS group with their concomitant intra-
venous infusions (mean ± SD, 1.6 ± 0.4 l versus 1.5 ±
0.5 l; p = 0.4). No other side effects related to the fur-
osemide or saline inhalation were reported.
Discussion
This study verifies that experimentally induced AH in
healthy individuals is substantially relieved by inhaled
furosemide compared to inhaled saline control. Further-
more, this study shows for the first time that this effect
was specific for the AH component of dyspnoea rather
than the sense of breathing effort.
Confirmation of AH relief by inhaled furosemide
The same stimulus to generate AH (hypercapnia with
constrained ventilation) and the same dose of inhaled fur-
osemide, delivered by the same method was used in the
Moosavi et al. (2007) study, which had demonstrated a
borderline treatment effect with inhaled furosemide rela-
tive to saline inhalation [21]. The current study provides
stronger evidence for a treatment effect with more robust
data and was powered to support a definitive outcome.
Table 1 Participant Characteristics
Total FSF SFS p value
Number 16 8 8 NS
Males: Female 9: 7 4: 4 5: 3 NS
Mean age, yr. (mean ± SD) 24.3 ± 3.7 23.6 ± 3.1 25 ± 4.3 NS
Caucasian: Non-Caucasian 11: 5 8: 0 3: 5 *0.031
Mean height, m (mean ± SD) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 NS
Mean weight, kg (mean ± SD) 79.5 ± 24 88.4 ± 28 70.6 ± 17 NS
History of Asthma 3 0 3 NS
Smoker/Ex-smoker: Never smoked 5: 11 3: 5 2: 6 NS
Previous experience with breathing apparatus 11 6 5 NS
Regular Sport: Sedentary 14: 2 7: 1 7: 1 NS
Abbreviations: FSF Mist order inhalation furosemide-saline-furosemide, SFS Mist order inhalation saline-furosemide-saline, NS not significant
Note: Experience of breathing apparatus included snorkelling, scuba diving or previous testing
*p < 0.05
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In contrast to the current findings, Banzett et al.
(2017) have recently published a study using similar
methods in 11 healthy volunteers indicating no signifi-
cant difference between relief of breathing discomfort by
inhaled furosemide and by inhaled saline [22]. The effect
of inhaled furosemide reported by Banzett et al. [22] was
greater than ours (mean ± SE: − 17 ± 3 versus − 11 ± 5
%VAS); this is likely to reflect the fact that they used a
higher dose (80 mg versus 40 mg) with controlled deliv-
ery on a mechanical ventilator. However, the effect of sa-
line was far greater in the study by Banzett et al. [22]
compared to this study (mean ± SE: − 13 ± 4 versus − 2.5
± 4 %VAS); we believe this is likely to be due to an en-
hanced placebo effect in their study as participants were
informed they were going to receive 2 active treatments
and one saline, whereas in reality they had one active
substance and two saline controls. Likewise, a second
study published by this group [23] also reported a sig-
nificant effect of inhaled saline (− 20 %VAS); this study
also used a similar deception to that alluded above
which is again likely to have enhanced the placebo effect.
While this second study used the same dose (40 mg) to
this current study they also reported a larger relief of
‘breathing discomfort’ with furosemide (− 20%VAS). This
Fig. 5 Overall changes in air hunger (AH) and work/effort (WE) associated with mist inhalations. Panel a. Mean ± SEM AH (left panels) and WE
(right panels) before and after furosemide inhalations (black bars) and before and after saline inhalations (grey bars) in the 8 individuals who were
allocated to the saline-furosemide-saline order of mist inhalations (top panels) and in 8 individuals who were allocated to the furosemide-saline-
furosemide order of mist inhalations (bottom panels). VAS ratings improved to a greater extent after furosemide compared to saline mist
inhalations for AH, but this pattern was not evident for WE. ETCO2 = end tidal CO2 (mean ± SD mmHg). Panel b. Least Squares Mean change in
VAS ratings before and after inhaled furosemide relative to the change before and after inhaled saline for AH and WE
Fig. 6 Individual data for change in visual analogue scale for air hunger (AH) and work/effort (WE). Individual change in visual analogue scale
ratings (VAS, % full scale) of AH at fixed test levels of PETCO2 (left panel), and of the sense of breathing WE at fixed test levels of tidal volume
(right panel) following inhaled furosemide (dark bars) and inhaled saline (grey bars). Closed bars indicate the average change in VAS for two
furosemide inhalations in half the participants (S1, 2, 4, 7, 10, 11, 14, 17) or the change in VAS for one furosemide inhalation in the other half.
Open bars indicate the average change in VAS for two saline inhalations in half the participants (S3, 5, 6, 8, 9, 12, 13, 15) or the change in VAS for
one saline inhalation in the other half. Inhalation of furosemide tends to produce a reduction in VAS after furosemide more often than after
saline for the AH test. For WE test reductions were evident for both inhaled furosemide and inhaled saline. Participants are arranged in order of
response to furosemide for the AH test
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could be explained by the different delivery method
used, which reduced loss of aerosol to the atmosphere
during expiration [23]. The different delivery method
they used reduces loss of aerosol to the atmosphere dur-
ing expiration and also assuming a similar absorption ef-
ficiency (both studies in healthy volunteers) could have
led to a greater and more prolonged interaction of fur-
osemide with lung stretch receptors thereby accounting
for a greater relief.
Specificity of relief
The relief of experimentally induced dyspnoea in healthy
individuals by inhaled furosemide was first shown by
Nishino et al. (2000) who induced dyspnoea by i) a com-
bination of inspiratory resistive load and hypercapnia,
and ii) breath-holding [24]. The first of these stimuli was
likely to have induced both WE and AH components of
dyspnoea. Since participants were instructed to rate re-
spiratory discomfort, both of these sensations could have
contributed to their ratings. The breath hold task may
have generated AH specifically but breath-holding is a
non-steady state. A subsequent study in healthy
individuals which specifically focused on experimentally
induced steady state AH generated similar levels of relief
[21]. This suggests that the inhaled furosemide may well
have specifically relieved the AH component in the stim-
uli used by Nishino et al. [24].
In contrast there is direct evidence that inhaled fur-
osemide does not affect the sensations associated with
respiratory effort during expiratory flow limited exercise
[25] or during exercise in the presence of external thor-
acic restriction in healthy individuals [26]. External thor-
acic restriction during exercise will elicit both AH and
WE component of dyspnoea [26, 27]. In the study by
Waskiw-Ford et al. (2018) individuals were asked to rate
the intensity and unpleasantness of their perceived dys-
pnoea without specifying which component of dyspnoea
to focus on [26]; it could be that the reported lack of re-
lief was because of the participants focusing on WE due
to the increased metabolic demand in this situation.
Breathing effort is assumed to arise from non-vagal af-
ferents from the chest wall, though a role for vagal affer-
ents from the lungs in the sense of breathing effort
cannot currently be discounted. Inhaled furosemide does
Fig. 7 Second dose effect. Left panels (a and c): Individual (n = 8) changes in VAS ratings of AH in response to first and second doses of inhaled
furosemide in the furosemide-saline-furosemide (FSF) group (a). Corresponding changes for the first and second doses of inhaled saline in the
saline-furosemide-saline (SFS) group (c). For the FSF group the second dose of furosemide had a greater reduction in AH relief than the first dose
in all but one participant. This was not true for the second dose of saline in the SFS group. Participants are arranged in order of response to first
dose of furosemide for the FSF group or first dose of saline for SFS group. Right panels (b and d): The mean reduction in AH for the first and
second dose of furosemide (b) and saline (d)
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appear to confer some benefit to exercising COPD pa-
tients but clinical dyspnoea in this scenario is likely to
be multifactorial and may not be specifically related to
respiratory effort [28]. It is generally accepted that AH
and WE components of clinical dyspnoea likely arise
from different neural pathways [8]. Previous reports have
provided evidence that the AH component of dyspnoea
is relieved by increased vagal afferent input from the
lungs [7, 29–31] or accentuated by absence of vagal af-
ferents from the lungs [32]. It is not known whether the
vagal afferent information has any role in the sense of
breathing effort - our data would suggest that vagal af-
ferents have no role in generation of WE.
Inhaled furosemide demonstrated a statistically signifi-
cant treatment effect that reached the accepted level for
the minimally important clinical difference (MCID) for
AH but not for WE [33]. There was some evidence of a
placebo effect with, on average, a slight reduction in AH
with inhaled saline. Some studies have shown a substan-
tial relief of laboratory-induced dyspnoea with saline in
over 30% of participants [22, 23]. However, O’Donnell
and colleagues found that overall the administration of
aerosol saline had little effect on experimentally induced
AH, provided the expectation of a treatment effect is
minimized [34]. In the current study, the careful blind-
ing procedures and instructions participants received en-
sured that they were unable to guess correctly when
they had received the active or placebo substance.
Ours is the first study to compare the effect of inhaled
furosemide and inhaled saline on AH and WE induced
separately in the same individuals allowing a direct com-
parison of treatment effects. Our data confirms that the
mechanism of dyspnoea relief by inhaled furosemide,
presumed to be via modulation of vagal afferents from
the lungs, specifically relates to AH and not WE.
Action of inhaled furosemide in the lungs
Inhaled furosemide is known to have many beneficial ef-
fects all of which appear to be mediated by actions on
the airway epithelium such as; improvements in exercise
induced asthma [35], inhibition of cough in asthmatics
and healthy volunteers [36–38] and induced broncho-
dilation in constant-load exercise testing in COPD [39].
The most likely explanation for relief of dyspnoea
with inhaled furosemide is modulation of lung mech-
anoreceptor feedback which replicates the sensation
of larger tidal volumes; thus experimentally induced
AH is relieved when tidal volume is increased [7, 40].
This is further supported by recent studies that have
reported a weak to moderate correlation between the
extent of dyspnoea relief with increased tidal volumes
(whilst free breathing) on the one hand, and relief by
inhaled furosemide on the other hand [22, 23]. Thus,
inhaled furosemide may be acting at least in part via
the same pathway.
Fig. 8 Dyspnoea Descriptors. Frequency with which each descriptive phrase was selected by participants to describe their experience during air
hunger tests (AH; left panel) and WE tests (WE; right panel). AH cluster of descriptors dominated the participants’ choice of the respiratory
sensations felt during the AH tests while the WE cluster of descriptors dominated the participants’ choice of the respiratory sensations felt
during the WE tests
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There are many different mechanoreceptors in the
lung including; slowly adapting pulmonary stretch recep-
tors (saPSR), rapidly adapting pulmonary stretch recep-
tors (raPSR), pulmonary and bronchial C-fibre receptors
(irritant receptors). These receptors collectively transmit
information to the central nervous system reporting the
tidal volume or the presence of airway irritants [41] . Ex-
posure of anaesthetized rats to inhaled furosemide has
demonstrated sensitization of saPSRs and desensitization
of raPSRs [6]. Evidence points to the saPSRs being the
most likely mechanoreceptor involved since the raPSRs
could not signal maintained volume changes as they
provide feedback relating more to transition between in-
spiration and expiration rather than the magnitude of
lung stretch [41, 42]. Studies in humans have suggested
that it is feedback concerning the overall ventilation ra-
ther than intra-breath variables that account for the level
of breathlessness perception [43, 44].
The diuretic effect of furosemide occurs via its
chloride channel blocking property affecting the
sodium-potassium-chloride co-transporter in the loop of
Henle [5]. Because the same membrane co-transporters
are expressed on vagal sensory neurons present in the air-
ways [45] it is possible that the modulation of pulmonary
stretch receptor sensitivity by inhaled furosemide may
occur by the same mechanism. In vitro studies of isolated
human lung tissue are needed to verify the precise mech-
anism of action of inhaled furosemide on pulmonary
stretch receptors.
No evidence for systemic action for dyspnoea relief with
inhaled furosemide
A potential alternative mechanism of action of fur-
osemide in relief of dyspnoea is via systemic effects
from absorption of the inhaled furosemide into the cir-
culation. Morélot-Panzini et al. (2018) estimated an ab-
sorption efficiency of up to 30% of the inhaled dose
[23]. From this information and assuming the maximal
level of efficiency, we estimated that a 40 mg inhaled
dose would result in 5 mg entering the systemic circu-
lation assuming a respiratory frequency of 12 breaths
per minute and a duty cycle of 0.4. This appears to be
higher than our estimate of systemic load of 1.5 mg
from inhalation of a nebulized dose of 40 mg in this
study. They also found that when given 15 mg intraven-
ously participants had an average 16%VAS improve-
ment in dyspnoea. It is suggested that in heart failure
systemic furosemide relieves dyspnoea by easing pul-
monary congestion and thereby reducing activation of
pulmonary C-fibre receptors. [46, 47]. This cannot ex-
plain relief of dyspnoea by intravenous furosemide in
healthy volunteers with no pulmonary congestion. The
authors suggest that this result could be explained by
the placebo effect as the participants were informed
that they would only receive active substances. In the
current study a dose of intravenous furosemide
(1.5 mg) that more closely matched the amount
absorbed from the inhaled dose was infused concur-
rently with inhaled saline. To maintain blinding intra-
venous saline was infused during furosemide inhalation.
In both cases the rate of infusion was set to match the
period of inhalation. We therefore consider the findings
of the current study showing no significant relief from
intravenous furosemide (mean ± SEM, − 2.5% ± 4) to
demonstrate more clearly that the AH relief by inhaled
furosemide is via direct actions within the lungs.
Further support for a mechanism of relief of AH via
direct actions in the lungs is provided by: i) direct expos-
ure of the lung tissue to furosemide in rat preparations
resulted in modulation of PSR afferent activity but not
when administered intravenously [6] ii) other studies in
which beneficial effects of furosemide have been evident
only when inhaled rather than administered via tablet
[35] iii) absence of haemodynamic changes with inhaled
furosemide in a study assessing wedge pressure mea-
surements in heart failure patients suggesting no sys-
temic mechanism of action [48] iv) absence of any
detectable difference in cumulative urine output between
the two groups in this study (SFS and FSF) which dis-
counts a mechanism of action related to diuresis.
Suggestion of ‘second dose’ effect
This study shows a beneficial cumulative effect of re-
peated furosemide inhalations (2x40mg). Ours is the
only study that has to our knowledge investigated the ef-
fect of a second dose of inhaled furosemide on experi-
mentally induced AH in healthy individuals. We noted a
significant reduction in AH ratings with the second dose
of furosemide in those who had the mists in the order
FSF (mean ± SEM − 10.2 ± 4.2 versus − 20.8 ± 4.6%VAS).
This was not seen for saline in those who had SFS so it
is unlikely to be an order effect (mean ± SEM − 6.5 ± 5.0
versus − 1.6 ± 7.9). It is possible that the first dose of fur-
osemide sensitizes the receptors so that the second dose
has an additive/cumulative effect. Another possibility is
from a carry-over effect where the inhaled furosemide is
still active in the lungs for up to at least an hour after
the first inhalation. Supporting this theory is Morélot-
Panzini et al. (2018) study reporting that the rate of
systemic absorption of inhaled furosemide is inversely
related to the extent of dyspnoea relief [23]. This sug-
gests that when the furosemide remains in the lungs, in
contact with the pulmonary stretch receptors for a lon-
ger duration, the action of furosemide on dyspnoea relief
is increased. An enhanced ‘second dose’ effect due to the
pharmacokinetics is a recognized phenomenon in psy-
chopharmocology [49].
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The question remains whether the ‘second dose’ effect
is related to sensitisation of stretch receptor-furosemide
interaction or a carry-over effect from the first dose of
furosemide due to incomplete removal of furosemide
from the lungs before the second dose. In the current
study the time between first furosemide mist and the
second was approximately 90 min. If we accept that on
average the furosemide stays within the lungs for up to
1 h based on the effect of a single dose on dyspnoea re-
lief [21] the length of time between the first and second
dose would go against a carryover effect to explain the
greater relief with the second dose. This is further sup-
ported by the fact that in the SFS group the time be-
tween the middle furosemide mist and the second saline
mist was less than 1 h and the pre second saline mist
AH remained below the pre first saline mist level (con-
sistent with a carryover effect of the middle furosemide
mist). We would therefore favour a sensitisation explan-
ation to account for the bigger relief from the second
dose of furosemide in the FSF group.
Technical considerations
Comparing AH versus WE tests it was difficult to achieve
a target level of 50% VAS with the WE test. This resulted
in the average VAS recordings for WE being lower
(40-50mmVAS) compared to the AH average VAS record-
ings (50-60 mm VAS). A higher resistance in the circuit
may have enabled both sensations to be studied at more
comparable levels of the VAS. Though unlikely, we cannot
discount the possibility that inhaled furosemide would not
have been effective in relieving WE if the WE test had also
been performed with a target level above 50% VAS.
It was noted that the time taken to nebulize 4 ml sa-
line to 4 ml of furosemide differed (duration of saline
mist was approximately 5-10 min and the furosemide
approximately 10-15 min), and this was also reported in-
dependently in another recent study [23]. In the current
study the unblinded researcher added saline or pre-
tended to add a solution to the nebulizer to ensure the
time taken to nebulize either solution was equal thereby
maintaining blinding.
The participant selection of descriptive phrases after
each breathing test confirmed that the different stimuli
elicited the required sensations and that the participants
were able to distinguish the different forms of dyspnoea
(AH vs WE). For the AH tests patients were instructed
to focus on and rate the form of dyspnoea indicated by
the phrases they had previously selected following the
initial exposure to the AH stimulus (during practice ses-
sions). If the participant reported other sensations such
as ‘breathing required more work’ during the AH tests,
they were coached not to include this sensation in their
ratings and to report them after each trial if present. For
the WE tests the participants were instructed to focus
on and rate the form of breathlessness indicated by the
phrases they had previously selected following the initial
exposure to the WE stimulus (during practice sessions).
If the participant reported other sensations such as the
AH descriptors, they were coached not to include this
sensation in their ratings but to report them after each
trial if present. After completing each trial, the partici-
pant described their sensations and picked phrases from
a given list of descriptive phrases and identified the top
3 most relevant. Subject selections following the AH and
WE tests were consistent with the type of stimulus. Par-
ticipants were also queried about any non-respiratory
sensations or external clues.
The participants and investigators were successfully
blinded to the study drugs and no participant was able
to correctly identify the correct order of mist inhalation.
There was no detectable taste difference detected by the
participants.
Applicability of conclusions
This study was performed in a narrow age range
(20-28 years). It is therefore not known whether the
same results will apply to older population. It is possible
that the sensitivity of PSRs alters with increasing age or
is affected by lung/heart disease. Most patients with
chronic dyspnoea will be much older than these study
participants.
Validity of conclusions
The test level of end tidal CO2 (ETCO2), the level
chosen to generate 50% VAS full scale for AH at base-
line, was different in the FSF group compared to the SFS
group (48 ± 0.4 mmHg vs 52 ± 0.3 mmHg). We do not
believe that this affects our data but it is interesting to
consider why. A post prandial rise in ETCO2 has been
demonstrated [50] but in our study there was no differ-
ence in consumption between the groups. They were
also tested over both morning and afternoon sessions
(FSF group: 3 in the morning, 5 in the afternoon. SFS
group: 4 in the morning, 4 in the afternoon). There were
no significant sex differences between the groups or dif-
ferences in smoking habit. By chance there was an un-
even distribution of ethnicity among the SFS and FSF
groups (p = 0.031). All participants in the FSF group
were Caucasian whereas the SFS group were not (Cauca-
sian =3, Others = 5). There is some suggestion in the lit-
erature that the level of dyspnoea is associated with
ethnicity [51]. This may explain some of the differences
seen in this study. There was also a trend for increased
weight (88 kg vs 70 kg) and for playing a wind instru-
ment (3 vs 1) in the FSF group. In the SFS group more
participants had a history of asthma (3 vs 0.) Although
these were not statistically significant some of these
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differences in characteristics may explain the different
ETCO2 levels in each group.
Limitations
Ventilation, tidal volume and inspiratory reserve vol-
umes were targeted at substantially different levels to
generate AH and WE rated at approximately 50% on the
VAS (9 vs 17 L/min; 0.75 vs 1.6 L, 1.8 vs 1.0 L respect-
ively). For both AH and WE the levels of these variables
were well matched before and after mist inhalations.
However, the frequency of vagal feedback from PSRs will
have been at a higher level for WE compared to AH test.
We cannot therefore discount the possibility that had
the WE test been done at the same level of afferent feed-
back from PSRs that the inhaled furosemide would have
relieved WE as well. As discussed above (specificity of
relief section) there is a lack of evidence for the role of
vagal afferent feedback from PSRs in WE modulation.
Furthermore from a practical viewpoint it would have
been very difficult to strictly control the ventilatory pa-
rameters between AH and WE tests while maintaining a
clear distinction in the quality of the dyspnoea generated
and a far greater resistive load would have been required
to generate 50% full scale on the VAS for WE.
In the VAS ratings of AH and WE we did not specific-
ally ask patients to rate intensity or unpleasantness and
it is likely that they rated a combination of both of these.
From this study we cannot say which component was
more predominant, however from previous studies we
know that AH is more unpleasant than WE [22].
Since instructions prior to intervention could influence
the outcome (e.g. amplify the placebo effects) we asked
participants at the end of the study which order they
thought they received the active and placebo substances.
They were either unsure or chose an order that was not
feasible (e.g. thought they received FFS or SSF or FSS
etc.) We do not have any evidence that the small placebo
effect we observed in this study arose from biasing the
participant expectations through the instructions given
prior to the start of the protocol.
Conclusion
Inhaled furosemide was effective at relieving the AH
component of dyspnoea but not the WE component.
This is consistent with a mechanism involving
sensitization of slowly adapting pulmonary stretch re-
ceptors leading to dyspnoea relief that specifically ap-
plies to the AH component, the most unpleasant form
of dyspnoea. We suggest that multi-dimensional dys-
pnoea assessment tools should be used to identify pa-
tients where AH predominates the symptom burden and
future clinical studies with inhaled furosemide should
target these patients, irrespective of their underlying
pathology, to optimise dyspnoea relief.
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